New treatment strategies for hepatitis C infection

doi:10.4254/wjh.v7.i17.2100

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9552)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

566

WORD

410

HTML

4448

Tables (1-1)

487

Sum=5911

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1400

Download

2241

Sum=3641

Aug 18, 2015 (publication date) through Nov 16, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Hepatol. Aug 18, 2015; 7(17): 2100-2109
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2100

Table 1 Direct-acting antivirals (clinical development status in parenthesis)

NS3/4A Protease inhibitors	NS5A inhibitors	Polymerase inhibitors
		NIs	NNIs
Telaprevir (approved)	Daclatasvir (approved)	Sofosbuvir (approved)	Dasabuvir (phase 3)
Boceprevir (approved)	Ledipasvir (phase 3)	Mericitabine (phase 2)	BMS-791325 (phase 3)
Simeprevir (approved)	Ombitasvir (approved)	VX-135 (phase 2)	PPI-383 (phase 1)
Asunaprevir (phase 3)	GS-5816 (phase 2)		GS-9669 (phase 2)
Danoprevir (phase 3)	ACH-2928 (phase 1)		TMC647055I (phase 2)
Paritaprevir (approved)	ACH-3102 (phase 2)		VX-222 (phase 2)
Vaniprevir (phase 3)	PPI-668 (phase 2)
Sovaprevir (phase 2)	PPI-461 (phase 1)
MK-5172 (phase 3)	GSK2336805 (phase 2)
ACH-2684 (phase 2)	Samatasvir (phase 2)
Narlaprevir (phase 2)	MK-8742 (phase 3)
Vedroprevir (phase 2)	BMS-824393 (phase 2)

NI: Nucleoside inhibitors; NNIs: Non-nucleoside inhibitors.

Full Size Table

Citation: Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7(17): 2100-2109
URL: https://www.wjgnet.com/1948-5182/full/v7/i17/2100.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i17.2100